<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303364</url>
  </required_header>
  <id_info>
    <org_study_id>C19-10</org_study_id>
    <nct_id>NCT04303364</nct_id>
  </id_info>
  <brief_title>CARdiomyopathy in Type 2 DIAbetes Mellitus</brief_title>
  <acronym>CARDIATEAM</acronym>
  <official_title>CARdiomyopathy in Type 2 DIAbetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic
      cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering
      approaches based on deep phenotyping (clinical, imaging and biological) information.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARDIATEAM study will address the uniqueness of DCM, and its progression towards heart
      failure (HF) with preserved ejection fraction (HFpEF) by recruiting a prospective CARDIATEAM
      cohort (n=1600 individuals) from existing cohorts using a defined set of selection criteria
      and will include type2-Diabetes mellitus (T2DM)and non-diabetic patients with a large
      spectrum of demographic, metabolic and cardiac clinical data. This will yield a wide range of
      T2DM - related phenotypes including common confounders such as BMI, smoking, age and blood
      pressure.

      To clarify the phenotype of DCM and to differentiate it from the other forms of HF such as
      HFpEF or HCM, CARDIATEAM will perform unbiased clustering analysis from an in-depth
      phenotyping of these patients' populations
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy</measure>
    <time_frame>3 years</time_frame>
    <description>Use of unsupervised clustering approaches based on deep phenotyping (clinical, imaging and biological) information</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the best clinical, biological, imaging and multi-OMICs predictors belonging to each identified cluster</measure>
    <time_frame>4 years</time_frame>
    <description>Specific focus on cluster(s) relating to a putative diabetic cardiomyopathy comparatively to other clusters [diagnostic perspective]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess prospective health outcomes (i.e. overall mortality, cardiovascular events and cardiac function) in the diabetic cardiomyopathy cluster identified</measure>
    <time_frame>5 years</time_frame>
    <description>Compare them to those from the other clusters and pre-defined patient groups [prognostic perspective]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy</measure>
    <time_frame>5 years</time_frame>
    <description>Better understand the underlying mechanisms responsible for establishment and progression of disease, based on OMICs data and causal inference modeling</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Cardiomyopathy, Diabetic</condition>
  <arm_group>
    <arm_group_label>Subjects without T2DM and without HF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM and with HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and without HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and HFpEF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without T2DM and with hypertrophic cardiomyopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with T2DM and with hypertrophic cardiomyopathy</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma EDTA, Serum, Paxgene RNA, Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Since CARDIATEAM aims to assess the uniqueness of DCM, it will include a group of
        non-diabetic non-HFpEF individuals with diversified characteristics relating to obesity,
        glucose intolerance and hypertension. Consequently, CARDIATEAM cohort will recruit both
        non-diabetic and diabetic patients with a large spectrum of demographic, metabolic and
        cardiac (heart failure vs. no heart failure) clinical data.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal LVEF AND absence of akinetic segment assessed by echocardiography
             (i.e.LVEF≥50%)

          -  Patients diagnosed according to the specific diagnostic criteria of each disease. For
             each group, the diagnosis will be based on current accepted criteria:

               -  HFpEF: LVEF≥50% AND presence/or history of symptoms or signs of HF AND
                  significant diastolic dysfunction OR NT-proBNP &gt;125 pg/Ml

               -  NoHFpEF:LVEF≥50% AND absenceofsymptoms or signs of HF

               -  T2DM:HbA1c≥6.5% (≥48mmol/L)AND Fasting Plasma Glucose≥7.0mmol/L (≥126 mg/dL) or
                  anti-diabetic treatment

               -  Normoglycemia defined as HbA1C &lt;5.7% (39mmol/L) AND Fasting Plasma Glucose &lt;5.6
                  mmol/L (100mg/dL)

               -  HCM: patients with non-obstructive HCM of sarcomeric cause (proven with common
                  genetic cause) and with LV wall thickness ≥ 15 mm in one or more myocardial
                  segments in the absence of abnormal afterload conditions.

          -  Suitable echocardiographic window

          -  Absence of history of coronary artery disease including history of myocardial
             ischaemia, myocardial infarction or percutaneous coronary intervention

          -  Absence of significant coronary artery disease (CAD) defined as

               -  a negative stress test: stress echocardiography, myocardial perfusion
                  scintigraphy or cardiac stress MRI performed within the 18 months before
                  inclusion OR

               -  the absence of coronary stenosis ≥50% on a cardiac computed tomography (CT) or
                  coronary angiography performed within the 18 months before inclusion

          -  Patient covered by a health insurance

        Exclusion Criteria:

        Diabetes mellitus other than type 2 (type 1, LADA, MODY, NODAT, etc.)

          -  Suboptimal echocardiographic window

          -  Significant valvular heart disease defined as severe aortic regurgitation or severe
             primary mitral regurgitation or aortic stenosis with a peak transvalvular velocity
             ≥3m/s or mitral stenosis with a mitral valve area &lt; 1.5cm2

          -  Chronic atrial fibrillation or any significant arrhythmia at inclusion

          -  Renal insufficiency defined as eGFR&lt;30 mL/min/1.73m2

          -  History of bariatric surgery

          -  Obstructive hypertrophic cardiomyopathy (definition: maximal gradient at rest &lt;30mmHg)

          -  Hypertrophic cardiomyopathy due to a non-sarcomeric etiology

          -  Life threatening comorbidities (i.e. cancer, end-stage heart failure, severe lung
             disease, cirrhosis)

          -  Pregnancy

          -  Lactating mother

          -  Any condition which in the Investigator's opinion makes it undesirable for the subject
             to participate in the study or which would jeopardize compliance with the protocol

          -  Inability to understand the local language

          -  Individuals deprived of liberty

          -  Protected persons (under guardianship or curatorship)

          -  Contra-indication to CMR

          -  Known hypersensitivity to gadolinium based product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève DERUMEAUX, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital HENRI-MONDOR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève DERUMEAUX, MD, PhD</last_name>
    <phone>+33 (0)603613517</phone>
    <email>genevieve.derumeaux@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne PIZARD, PhD</last_name>
    <phone>+33(0)149814398</phone>
    <email>anne.pizard@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Outpatient Department at Hôpital Henri Mondor.</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Geneviève Derumeaux, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cyrille Bergerot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>department of diabetology and nutrition, APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Dutour, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetology departement, Lariboisière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-François Gautier, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetology department, Cochin Institute</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Boitard, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Étienne Larger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Charron, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Nikolaus Marx, Univ.-Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>M. Louis Handoko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG), Cardiology/Cardio Research</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Rudolf de Boer, Prof dr.</last_name>
    </contact>
    <investigator>
      <last_name>Victor Zwartkruis, drs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch ziekenhuis Maastricht, Cardiology</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephane Heymans, Prof, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vanessa van Empel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht, Cardiology (DHL)</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Folkert Asselbergs, Prof, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Rodríguez Palomares, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Bermejo, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José L. Zamorano, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Dundee, Div of Molecular&amp;Clinical Medicine</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Chim Lang, Prof, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type2 Diabetes Mellitus</keyword>
  <keyword>Heart Failure with preserved ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

